SDHA related tumorigenesis: a new case series and literature review for variant interpretation and pathogenicity
Year: 2017
Type: article
Abstract: Purpose To evaluate the role of germline SDHA mutation analysis by (1) comprehensive literature review, (2) description of novel germline SDHA mutations and (3) in silico structural prediction analysis of missense substitutions in SDHA. Patients and methods A systematic literature review and a retrospective review of the molecular and clinical features of patients identified with putative germline variants in UK molecular genetic laboratories was performed. To evaluate the molecular consequences of SDHA missense variants, a novel model of the SDHA/B/C/D complex was generated and the structural effects of missense substitutions identified in the literature, our UK novel cohort and a further 32 “control missense variants” were predicted by the mCSM computational platform. These structural predictions were correlated with the results of tumor studies and other bioinformatic predictions. Results Literature review revealed reports of 17 different germline SDHA variants in 47 affected individuals from 45 kindreds. A further 10 different variants in 15 previously unreported cases (seven novel variants in eight patients) were added from our UK series. In silico structural prediction studies of 11 candidate missense germline mutations suggested that most (63.7%) would destabilize the SDHA protomer, and that most (78.1%) rare SDHA missense variants present in a control data set (ESP6500) were also associated with impaired protein stability. Conclusion The clinical spectrum of SDHA‐associated neoplasia differs from that of germline mutations in other SDH‐subunits. The interpretation of the significance of novel SDHA missense substitutions is challenging. We recommend that multiple investigations (e.g. tumor studies, metabolomic profiling) should be performed to aid classification of rare missense variants before genetic testing results are used to influence clinical management.
DOI: 10.1002/mgg3.279
Authors: Ruth T. Casey, David B. Ascher, Eleanor Rattenberry, Louise Izatt, Katrina A. Andrews, Helen L. Simpson, Benjamen Challis, Soo‐Mi Park, Venkata R. Bulusu, Fiona Lalloo, Douglas E. V. Pires, Hannah West, Graeme R. Clark, Philip S. Smith, James Whitworth, Thomas G. Papathomas, Phillipe Taniere, Rosina Savisaar, Laurence D. Hurst, Emma R. Woodward, Eamonn R. Maher
Institutions: University of Cambridge, National Institute for Health and Care Research, Addenbrooke's Hospital, NIHR Cambridge Biomedical Research Centre, The University of Melbourne, Birmingham Women's Hospital, Guy's Hospital, Cambridge University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, St Mary's Hospital, Fiocruz Minas, Fundação Oswaldo Cruz, King's College Hospital, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, University of Bath
Language: English
Topic: Genomics and Rare Diseases
Subfield: Genetics
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,900
Funders: Sanofi, Newton Fund, National Institute for Health and Care Research, British Heart Foundation, Research Councils UK, Boehringer Ingelheim Fonds, Gwangju Institute of Science and Technology, Cambridge University Hospitals, Fundação de Amparo à Pesquisa do Estado de Minas Gerais, Conselho Nacional das Fundações Estaduais de Amparo à Pesquisa, Medical Research Council, National Health and Medical Research Council, H2020 European Research Council
OpenAlex ID: W2594240795
